Managers / Q1 2026
Data Collective IV GP, LLC
CIK 0001664974 · 270 UNIVERSITY AVENUE, PALO ALTO, CA, 94301 · 650-521-7814
Summary
Data Collective IV GP, LLC reported $56M in U.S.-listed holdings across 4 positions for Q1 2026.
The portfolio is heavily concentrated: EVLV alone accounts for 49.6% of reported value.
Compared with Q4 2025, the fund opened 2 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 85.6% · $48M
- Other · 14.4% · $8M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Horizon Quantum Holdings Ltd | NEW | +915.2K | 915.2K | +$8M | $8M |
| DFTXDefinium Therapeutics, Inc. (MindMed) | NEW | +100.3K | 100.3K | +$2M | $2M |
| Mind Medicine (MindMed) Inc. | SOLD OUT | −100.3K | 0 | −$1M | $0 |
| RXRXRecursion Pharmaceuticals, Inc. | HELD | +0 | 5.94M | −$6M | $18M |
| EVLVEvolv Technologies Holdings, Inc. | HELD | +0 | 4.59M | −$5M | $28M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | EVLVEvolv Technologies Holdings, Inc.history → | COM CL A | 49.63% | $28M | 4.59M |
| 2 | RXRXRecursion Pharmaceuticals, Inc.history → | CL A | 32.60% | $18M | 5.94M |
| 3 | Horizon Quantum Holdings Ltd | CL A ORD SHS | 14.38% | $8M | 915.2K |
| 4 | DFTXDefinium Therapeutics, Inc. (MindMed)history → | COM SHS | 3.39% | $2M | 100.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $56M | 4 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $59M | 3 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $68M | 4 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $130M | 5 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $87M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $226M | 6 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $163M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $143M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $115M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 5 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $106M | 5 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $135M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $94M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $95M | 6 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 5 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $741M | 5 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.